Organon announced it will voluntarily supplement its definitive proxy statement for the proposed merger with Sun Pharma after a New Jersey lawsuit challenged disclosures.
Key Highlights:
- Complaint filed July 6 seeks to enjoin the July 23 stockholder vote, alleging proxy disclosures were incomplete; motion for preliminary injunction pending.
- Organon denies the allegations but will supplement the definitive proxy to avoid delay, costs and uncertainty while denying legal necessity.
- Proxy supplements add a $700M preliminary aggregate synergy estimate and describe board deliberations and advisor analyses.
- Updated Organon projections: 2026 revenue $6,252M, adjusted EBITDA $1,894M, net debt $7,530M and ~284.9M fully diluted shares as of April 24, 2026.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.